AMGN : Summary for Amgen Inc. - Yahoo Finance

U.S. Markets closed

Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
141.19-3.92 (-2.70%)
At close: 4:00 PM EST

140.80 -0.39 (-0.28%)
After hours: 6:01 PM EST

People also watch:
BIIBGILDCELGMRKBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close145.11
Open143.52
Bid141.05 x 200
Ask141.30 x 100
Day's Range139.66 - 143.87
52 Week Range133.64 - 176.85
Volume6,336,444
Avg. Volume3,771,210
Market Cap105.03B
Beta1.51
PE Ratio (TTM)14.13
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield4.00 (2.78%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Trump Vow On Drug Prices Fails To Stop Rally; Apple Retakes Prior Buy Point
    Investor's Business Daily5 hours ago

    Trump Vow On Drug Prices Fails To Stop Rally; Apple Retakes Prior Buy Point

    The market is rallying broadly late Wednesday and the Nasdaq and big-cap techs are regaining strength. Apple is back above a prior entry.

  • Barrons.com5 hours ago

    4 Stocks Set for Dividend Hikes Next Week

    Analysts at Markit Dividend Forecasting have identified four companies likely to raise their dividends next week. Below is their list, plus a few lines from their analysis: Amgen (AMGN) is expected to hike its dividend 10% for a yield of 3.1% on December 14. Analyst Leaf Ye writes: AMGN has increased its dividend in December each year since the maiden payment in 2011, with no exceptions, and we expect the company to maintain this pattern... Our projected increase for FY’17 maintains the 35% payout ratio taking into account consensus earnings estimates for the upcoming year.

  • Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus
    Zacks11 hours ago

    Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus

    This week, several biotech companies were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline candidates.